Product Document Searching Made Easy by 2D Code! | TCI Life Science News July 2026 | [Product Highlights] Mitochondrial Membrane Potential... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 61825-94-3 | Product Number: O0372
Oxaliplatin
×
Purity:
Synonyms:
- (trans-1,2-Cyclohexanediamine)oxalatoplatinum(II)
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 100MG |
$229.00
|
10 | ≥40 | It can be shipped in about 2 weeks after ordering |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | O0372 |
| Molecular Formula / Molecular Weight | C__8H__1__4N__2O__4Pt = 397.29 |
| Physical State (20 deg.C) | Solid |
Storage Temperature 
|
Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Moisture Sensitive,Heat Sensitive |
| Packaging and Container
|
100MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 61825-94-3 |
| Reaxys Registry Number | 14621501 |
| PubChem Substance ID | 125309438 |
| Merck Index (14) | 6912 |
| MDL Number | MFCD00866327 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Elemental analysis(Nitrogen) | 6.70 to 7.40 % |
| NMR | confirm to structure |
Properties (reference)
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H315 : Causes skin irritation. H319 : Causes serious eye irritation. H317 : May cause an allergic skin reaction. H334 : May cause allergy or asthma symptoms or breathing difficulties if inhaled. H341 : Suspected of causing genetic defects. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P261 : Avoid breathing dust. P272 : Contaminated work clothing should not be allowed out of the workplace. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P284 : Wear respiratory protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P342 + P311 : If experiencing respiratory symptoms: Call a POISON CENTER/doctor. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P304 + P340 : IF INHALED: Remove person to fresh air and keep comfortable for breathing. P333 + P313 : If skin irritation or rash occurs: Get medical advice/ attention. P405 : Store locked up. |
Related Laws:
| RTECS# | TP2275850 |
Transport Information:
| H.S.code* | 2843.90-000 |
Application
Platinum Coordination Complexes as Antitumor Agents
The development of platinum coordination complexes as antitumor agents began in the 1960s, and the highest antitumor activity was exhibited by cisplatin [D3371], approved by FDA in 1978. Improved versions carboplatin [C2043] and oxaliplatin were developed to avoid the serious side effects and the problem with resistance associated with the use of cisplatin.1-5)
The platinum complexes diffuse to the tumor cell, where they undergo hydrolysis displacement of their one chloride or carboxylate group leading to a platinum cation. The resulting cation coordinates to the guanine N7-position of DNA give a coordination cation. Then, intrastrand cross-linking occurs to anther guanine via further hydrolysis displacement of the remaining chloride or carboxylate. The forming [Pt(NH2R)2]2+ ― DNA complex distort the DNA helix (Fig. 1 and 2)6). Thus, DNA duplication is hindered, which ultimately triggers tumor cell apoptosis.3)
The platinum complexes diffuse to the tumor cell, where they undergo hydrolysis displacement of their one chloride or carboxylate group leading to a platinum cation. The resulting cation coordinates to the guanine N7-position of DNA give a coordination cation. Then, intrastrand cross-linking occurs to anther guanine via further hydrolysis displacement of the remaining chloride or carboxylate. The forming [Pt(NH2R)2]2+ ― DNA complex distort the DNA helix (Fig. 1 and 2)6). Thus, DNA duplication is hindered, which ultimately triggers tumor cell apoptosis.3)
References
- 1)G. Mathe, Y. Kidani, M. Segiguchi, M. Eriguchi, G. Fredj, G. Peytavin, J. L. Misset, S. Brienza, F. de Vassals, E. Chenu, C. Bourut, Biomed. Pharmacother. 1989, 43, 237.
- 2)L. R. Kelland, S. Y. Sharp, C. F. O’Neill, F. I. Raynaud, P. J. Beale, I. R. Judson, J. Inorg. Biochem. 1999, 77, 111.
- 3)D. Wang, S. J. Lippard, Nat. Rev. Drug Discov. 2005, 4, 307.
- 4)S. Trzaska, Chem. Eng. News 2005, 83, 3.
- 5)L. P. Martin, T. C. Hamilton, R. J. Schilder, Clin. Cancer Res. 2008, 14, 1291.
- 6)A. Gelasco, S. J. Lippard, Biochemistry, 1998, 37, 9230.
Application
Reagent for pain model
References
- Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat
- Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat
- Mexiletine reverses oxaliplatin-induced neuropathic pain in rats
- N. Egashira, S. Hirakawa, T. Kawashiri, T. Yano, H. Ikesue, R. Oishi, J. Pharmacol. Sci. 2010, 112, 473.
Application
Pharmacology study
References
- Cellular and molecular pharmacology of oxaliplatin
- E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, E. Cvitkovic, Mol. Cancer Therapeutics 2002, 1, 227.
- Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA
- J. M. Woynarowski, W. G. Chapman, C. Napier, M. C. S. Herzig, P. Juniewicz, Mol. Pharmacol. 1998, 54, 770.
- Oxalato-platinum or l-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Enter TCI Product Number
Enter KISHIDA Product Number
4-5 alphanumeric characters before the hyphen
7 alphanumeric characters
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
• The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
• Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
• If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
• Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
The requested analytical chart is not available. Sorry for the inconvenience.